• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, April 21, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Funding research toward treating the root cause of neurodegenerative disease

Bioengineer by Bioengineer
March 26, 2021
in Chemistry
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Professor and GlycoNet Investigator Simonetta Sipione’s research awarded major grant from the Canadian Institutes of Health Research

IMAGE

Credit: GlycoNet

Dr. Simonetta Sipione, GlycoNet Investigator and Professor in the Department of Pharmacology at the University of Alberta, was recently awarded a major five-year grant from the Canadian Institutes of Health Research (CIHR), worth $1.04 million. The project builds upon work previously funded by GlycoNet.

The project aims to clarify the therapeutic role of gangliosides, a family of glycolipid molecules that have properties of both lipids and carbohydrates, in the brain.

“These gangliosides are highly enriched in the healthy brain. They help brain cells communicate with each other and with the environment,” says Sipione, lead Investigator on the project.

“During aging and in some cases of neurodegenerative diseases, including Huntington’s disease and Parkinson’s disease, the level of some of the gangliosides is lower in the patient’s brain,” says Sipione. “We are interested in finding out why and developing a viable treatment that tackles the root of the disease, not just the symptoms.”

Currently, patients who have neurodegenerative diseases are usually prescribed with medications to improve movement and fight depression. However, none of these medications address the disease cause, which is the accumulation of toxic proteins in the brain. Finding ways to prevent this toxic buildup will turn the table on current methods to treat these diseases.

Previously, Sipione’s team was able to slow down neurodegeneration in a mouse model of Huntington’s disease through injection of a type of ganglioside called GM1 into the mouse brain.

“Restoring the level of GM1 in the brain could be a potential treatment for those who experience, or show signs of, neurodegeneration,” says Sipione. Now, her team is investigating the mechanism of action, as this knowledge would shed light on other aspects in neuro- and glycoscience and help develop treatments.

According to Sipione, the CIHR grant will enable her team to find out how GM1 helps the brain dispose of, or even prevent, the buildup of toxic proteins.

“To use a simple analogy, toxic proteins are like garbage and your brain is like a house. If garbage accumulates in the house and no one throws it out, your house is going to smell. We think GM1 and other gangliosides have a key role in instructing brain cells so that the garbage (toxic proteins) can be thrown out properly and eliminated by trash collectors, which are other biomolecules in the brain,” she adds. “Our studies will help determine the underlying mechanism of GM1’s therapeutic effects and whether other similar molecules could be a novel treatment, not only for Huntington’s disease, but also potentially for Parkinson’s and Alzheimer’s disease.”

The Huntington Society of Canada reports that approximately 1 in 7,000 people in Canada has Huntington’s disease. Another report from The Alzheimer’s Society suggests that over 500,000 Canadians are living with dementia that results from neurogenerative disorders including Alzheimer’s and Parkinson’s disease. As seniors in Canada are a rapidly growing segment of the population, by 2031, it is estimated that the number will increase to 937,000.

Sipione, who trained as a biochemist, believes that her laboratory’s interdisciplinary approach provides a unique opportunity to uncover issues central to brain health. Her goal is to leverage knowledge from her research discoveries to create tangible benefits for people both in Canada and worldwide.

###

Media Contact
Ali Chou
[email protected]

Original Source

https://canadianglycomics.ca/funding-research-toward-treating-the-root-cause-of-neurodegenerative-disease/

Tags: AgingAlzheimerBiochemistryGrants/FundingHealth CareMedicine/HealthneurobiologyPhysiology
Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Direct observation of the ad- and desorption of guest atoms into a mesoporous host

April 21, 2021
IMAGE

New process breaks down biodegradable plastics faster

April 21, 2021

Bubble with titanium trigger titanic explosions

April 21, 2021

To design truly compostable plastic, scientists take cues from nature

April 21, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    A sturdier spike protein explains the faster spread of coronavirus variants

    44 shares
    Share 18 Tweet 11
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    56 shares
    Share 22 Tweet 14
  • Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    61 shares
    Share 24 Tweet 15
  • New evidence in search for the mysterious Denisovans

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

UrbanizationUrogenital SystemVehiclesVirusZoology/Veterinary ScienceWeather/StormsWeaponryViolence/CriminalsUniversity of WashingtonVaccineVaccinesVirology

Recent Posts

  • Microplastics affect global nutrient cycle and oxygen levels in the ocean
  • Direct observation of the ad- and desorption of guest atoms into a mesoporous host
  • Great white feeding ground
  • Verbal fluency deficits in multiple sclerosis may reflect impaired language ability
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In